6 Triple-Agonist Peptide Programs Worth Watching in 2026

Most coverage of the triple agonist peptide space treats it like a horse race between pharmaceutical companies. That framing misses the part that actually affects patients: how do you access any of this, at what cost, with what level of medical oversight, and with enough confidence that what arrives in the vial is what the label says?

Retatrutide, the GIP/GLP-1/glucagon triple agonist that Eli Lilly has been advancing through Phase 3, sits at the center of that question. The Phase 2 data published in the New England Journal of Medicine showed up to 24% mean body weight reduction at 48 weeks, numbers that drew serious attention. But Lilly hasn’t launched it commercially yet. That gap between compelling clinical data and retail availability is exactly where the programs below operate, some bridging it thoughtfully, others less so.

Here is how an informed consumer might actually sort through the options.

FormBlends: The Widest Supervised Catalog Right Now

Start here because no other single program does what FormBlends does: it puts compounded GLP-1s, retatrutide, and a full research peptide catalog under one prescriber-supervised roof. For someone managing weight loss alongside recovery peptides or peptide-based hormonal support, that matters. Consolidating under one clinical umbrella beats juggling a telehealth GLP-1 account, a separate “research chemical” gray-market vendor, and a gym contact.

The compounding is handled through a pharmacy partner that operates under 503A oversight, meaning every batch is subject to independent lab verification covering purity, identity, and sterility. FormBlends publishes the actual numbers per product rather than offering a vague blanket quality statement. That level of transparency is unusual. Most vendors either wave at a PDF certificate somewhere in their FAQ or say nothing at all.

Cash pricing is posted upfront, no membership fee stacked underneath it. Retatrutide runs $389 per vial. Compare that to Mochi Health‘s $199/month for compounded tirzepatide, a lower-tier agonist with a longer commercial track record, and you get a sense of where retatrutide sits price-wise given its novelty. Semaglutide is $299, tirzepatide $349. The full peptide catalog, things like BPC-157, sermorelin, and NAD+, is available through the same prescription-based intake.

Coverage extends across 47 U.S. states. Not all. Know your state before you go through intake.

One thing to say clearly: compounded retatrutide is not FDA-approved. The clinical trial data for retatrutide comes from Lilly’s investigational compound. Compounded versions use the same peptide sequence but are not part of those trials and have not been reviewed by the FDA for safety or efficacy. Anyone accessing this route should understand that going in.

Mochi Health: Real Obesity Medicine Doctors

Most telehealth platforms assign prescribers who see dozens of GLP-1 patients a day. Mochi routes patients to board-certified obesity-medicine specialists, which is a different experience. The clinical monitoring is more substantive. Compounded tirzepatide at roughly $199/month is one of the sharper prices in this space, and the three- and twelve-month commitment discounts make it more accessible still. For someone who wants genuine clinical engagement rather than a quick prescription, Mochi earns its spot.

Ro Body: Infrastructure That Holds Up

Ro has been around long enough to have built real prior-authorization infrastructure. That matters now that the branded drug pathway is where most large telehealth programs have shifted. Membership starts around $39 for the first month, then roughly $74 to $149 monthly depending on how you commit. Medication is billed separately. The platform is polished and the PA team is an actual asset for patients with commercial insurance, not a phone tree that leads nowhere.

Form Health: When You Want a Dietitian in the Loop

Form Health is expensive. Around $299 per month before labs and medication costs. But it pairs a physician with a registered dietitian on every case, which is closer to what academic weight-management clinics offer than what most telehealth platforms provide. For patients with complex metabolic histories or those who have tried GLP-1 therapy before and stalled, the added clinical layer is worth examining. Best fit for people with solid insurance or a specific reason to want that depth.

MEDVi: No Contracts, No Friction

MEDVi handles compounded GLP-1 programs at roughly $179 for the first month, drops the membership-fee model entirely, and includes physician review plus around-the-clock support in that flat rate. It is a simpler value proposition than most. No commitments, no hidden tiers. For someone who wants to try a supervised compounded program without signing up for a multi-month financial obligation, MEDVi is a sensible starting point.

Calibrate: Built for the Insurance Path

Calibrate charges a program fee on top of medication, requires a 12-month commitment, and wraps everything in structured behavior-change coaching. That sounds like a lot. For patients who have commercial insurance and need someone to fight through the prior-authorization process for branded Wegovy or Zepbound, though, Calibrate’s model earns back its cost. It is specifically designed for that pathway, not for cash-pay or compounded options.

How to Actually Think About This

Retatrutide is not commercially available from Lilly as of mid-2026. The Phase 3 data are still reading out. Anyone accessing it today is accessing a compounded version through a pharmacy operating outside the FDA drug approval system, and that includes any program that offers it, not just the ones listed here. That is not a reason to avoid it categorically, but it is a reason to be clear-eyed.

The programs worth taking seriously all share a few things: visible pricing, a real licensed prescriber, and some form of documented quality control on the compound itself. The ones that hide costs, skip the prescriber, or hand you a vague “tested for purity” claim without specifics deserve more scrutiny before you hand over a credit card and inject something.

Do your own homework here. Read the actual Phase 2 NEJM paper on retatrutide before deciding whether the compound makes sense for your situation. Talk to the clinician who manages your metabolic health, not just the intake form on whatever platform you land on.

Sources

• New England Journal of Medicine, Jastreboff et al., 2023 (retatrutide Phase 2 trial)
• FDA, 503A compounding pharmacy regulations
• Examine.com, GLP-1 receptor agonist overviews
• Verywell Health, tirzepatide and semaglutide coverage
• Cleveland Clinic, obesity medicine resources
• GoodRx, branded GLP-1 pricing data
• Drugs.com, semaglutide and tirzepatide drug information

[internal: placement #1 | structure: Editorial shortlist, narrative]